FULCRUM WEALTH ADVISORS, LLC
Position in SLS — SELLAS Life Sciences Group, Inc.
CIK 2108790
BELLEVUE, WA
Position in SLS
as of Jun 30, 2026
· filed Jul 21, 2026
Position Value
$1,081,214
+$619,083 QoQ
Shares Held
73,253
-32.9% QoQ
Ownership
0.036%
of shares outstanding
% of Portfolio
1.06%
of 13F equity value
Holder Rank
#60
of 192 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in SLS Over Time
Shares Held
Position Value (USD)
Derivatives in SLS
reported options exposure · as of Mar 31, 2026CallValue
$65,565
CallShares
15,500
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026FULCRUM WEALTH ADVISORS, LLC holds $1,081,214 across 1 Biotechnology name. SLS ranks #1 (100.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SLS |
SELLAS Life Sciences Group, Inc.
This page
|
73,253 | $1,081,214 |
All Filings in SLS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,081,214 | 73,253 | Shares | Sole | 2026-07-21 | |
| 2026-03-31 | $65,565 | 15,500 | Call | Sole | 2026-04-22 | |
| 2026-03-31 | $462,131 | 109,251 | Shares | Sole | 2026-04-22 | |
| 2025-12-31 | $47,125 | 12,500 | Call | Sole | 2026-02-02 | |
| 2025-12-31 | $183,463 | 48,664 | Shares | Sole | 2026-02-02 | |
| No filing history on record for this holder in this stock. | ||||||